CN111920785B - 异甘草酸或其盐的吸入制剂及其应用 - Google Patents
异甘草酸或其盐的吸入制剂及其应用 Download PDFInfo
- Publication number
- CN111920785B CN111920785B CN202010842414.4A CN202010842414A CN111920785B CN 111920785 B CN111920785 B CN 111920785B CN 202010842414 A CN202010842414 A CN 202010842414A CN 111920785 B CN111920785 B CN 111920785B
- Authority
- CN
- China
- Prior art keywords
- inhalation
- particle size
- formulation
- magnesium isoglycyrrhizinate
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 74
- 150000003839 salts Chemical class 0.000 title abstract description 23
- 239000001685 glycyrrhizic acid Substances 0.000 title description 9
- 229960004949 glycyrrhizic acid Drugs 0.000 title description 9
- OJIXTCWHYBRFHL-LEEOIRFPSA-L magnesium (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aS,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Mg++].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C(O)=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O OJIXTCWHYBRFHL-LEEOIRFPSA-L 0.000 claims abstract description 141
- 239000003814 drug Substances 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims description 85
- 238000009472 formulation Methods 0.000 claims description 80
- 239000002245 particle Substances 0.000 claims description 74
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 45
- 239000008101 lactose Substances 0.000 claims description 44
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 40
- 239000002775 capsule Substances 0.000 claims description 33
- 238000009826 distribution Methods 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 27
- 238000011282 treatment Methods 0.000 claims description 27
- 239000000796 flavoring agent Substances 0.000 claims description 18
- 235000013355 food flavoring agent Nutrition 0.000 claims description 12
- 206010036790 Productive cough Diseases 0.000 claims description 10
- 229940098458 powder spray Drugs 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 28
- 239000002253 acid Substances 0.000 abstract description 24
- 208000023504 respiratory system disease Diseases 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 42
- 239000012669 liquid formulation Substances 0.000 description 40
- 235000002639 sodium chloride Nutrition 0.000 description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 35
- 230000000694 effects Effects 0.000 description 31
- 239000006199 nebulizer Substances 0.000 description 28
- 239000000443 aerosol Substances 0.000 description 25
- 210000004072 lung Anatomy 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000007788 liquid Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000010419 fine particle Substances 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 210000000265 leukocyte Anatomy 0.000 description 15
- 238000005303 weighing Methods 0.000 description 15
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 14
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 238000011049 filling Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 239000008215 water for injection Substances 0.000 description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 12
- 238000000889 atomisation Methods 0.000 description 12
- 210000004969 inflammatory cell Anatomy 0.000 description 12
- 239000011777 magnesium Substances 0.000 description 12
- 229910052749 magnesium Inorganic materials 0.000 description 12
- 206010019799 Hepatitis viral Diseases 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 210000000440 neutrophil Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 201000001862 viral hepatitis Diseases 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 10
- 235000011114 ammonium hydroxide Nutrition 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 230000008595 infiltration Effects 0.000 description 10
- 238000001764 infiltration Methods 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- 238000007873 sieving Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000001684 chronic effect Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000003437 trachea Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 235000011121 sodium hydroxide Nutrition 0.000 description 7
- 208000024794 sputum Diseases 0.000 description 7
- 210000003802 sputum Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 239000003172 expectorant agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 6
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 6
- 235000019410 glycyrrhizin Nutrition 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010014561 Emphysema Diseases 0.000 description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 244000099147 Ananas comosus Species 0.000 description 4
- 235000007119 Ananas comosus Nutrition 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 244000246386 Mentha pulegium Species 0.000 description 4
- 235000016257 Mentha pulegium Nutrition 0.000 description 4
- 235000004357 Mentha x piperita Nutrition 0.000 description 4
- 240000008790 Musa x paradisiaca Species 0.000 description 4
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 239000010630 cinnamon oil Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000001050 hortel pimenta Nutrition 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 4
- 239000001683 mentha spicata herb oil Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 235000019477 peppermint oil Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 235000019721 spearmint oil Nutrition 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000009798 acute exacerbation Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- -1 compound magnesium isoglycyrrhizinate Chemical class 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960001031 glucose Drugs 0.000 description 3
- 235000001727 glucose Nutrition 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 235000011167 hydrochloric acid Nutrition 0.000 description 3
- 235000011477 liquorice Nutrition 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940037128 systemic glucocorticoids Drugs 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 206010054949 Metaplasia Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000024863 abnormal sputum Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 210000001552 airway epithelial cell Anatomy 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- VYQRBKCKQCRYEE-UHFFFAOYSA-N ctk1a7239 Chemical compound C12=CC=CC=C2N2CC=CC3=NC=CC1=C32 VYQRBKCKQCRYEE-UHFFFAOYSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000015689 metaplastic ossification Effects 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 101100384806 Mus musculus Arcn1 gene Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical group C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 208000003441 Transfusion reaction Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000037080 exercise endurance Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 210000002468 fat body Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610237175 | 2016-04-15 | ||
| CN2016102371753 | 2016-04-15 | ||
| PCT/CN2017/080583 WO2017177966A1 (zh) | 2016-04-15 | 2017-04-14 | 异甘草酸或其盐的吸入制剂及其在制备治疗呼吸系统疾病药物中的应用 |
| CN201780018629.0A CN109069442B (zh) | 2016-04-15 | 2017-04-14 | 异甘草酸或其盐的吸入制剂及其应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780018629.0A Division CN109069442B (zh) | 2016-04-15 | 2017-04-14 | 异甘草酸或其盐的吸入制剂及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111920785A CN111920785A (zh) | 2020-11-13 |
| CN111920785B true CN111920785B (zh) | 2022-05-20 |
Family
ID=60042326
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010842414.4A Active CN111920785B (zh) | 2016-04-15 | 2017-04-14 | 异甘草酸或其盐的吸入制剂及其应用 |
| CN201780018629.0A Active CN109069442B (zh) | 2016-04-15 | 2017-04-14 | 异甘草酸或其盐的吸入制剂及其应用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780018629.0A Active CN109069442B (zh) | 2016-04-15 | 2017-04-14 | 异甘草酸或其盐的吸入制剂及其应用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20190117568A1 (enExample) |
| EP (1) | EP3443954A4 (enExample) |
| JP (2) | JP7166929B2 (enExample) |
| KR (1) | KR102410183B1 (enExample) |
| CN (2) | CN111920785B (enExample) |
| AU (1) | AU2017251548B2 (enExample) |
| BR (1) | BR112018071208A2 (enExample) |
| EA (1) | EA201892350A1 (enExample) |
| MX (1) | MX394106B (enExample) |
| MY (1) | MY204600A (enExample) |
| PH (1) | PH12018502195A1 (enExample) |
| SG (2) | SG11201809042SA (enExample) |
| WO (1) | WO2017177966A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119345161A (zh) * | 2024-12-25 | 2025-01-24 | 江苏长泰药业股份有限公司 | 一种丙酮酸钠雾化吸入制剂及其制备方法和应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396368A (zh) * | 2007-09-29 | 2009-04-01 | 江苏正大天晴药业股份有限公司 | 异甘草酸或其盐在治疗过敏性鼻炎中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4891221A (en) * | 1988-11-23 | 1990-01-02 | Edward Shanborm | Whole blood antiviral process and composition |
| WO2005004913A1 (ja) * | 2003-07-09 | 2005-01-20 | Anges Mg, Inc. | デコイを含む薬学的組成物およびその使用方法 |
| JP2009513529A (ja) * | 2003-07-11 | 2009-04-02 | グラクソ グループ リミテッド | ステアリン酸マグネシウムを含む医薬製剤 |
| CN101023953B (zh) * | 2006-07-24 | 2010-05-12 | 南开大学 | 治疗支气管哮喘的组合物 |
| CN101190232B (zh) * | 2006-11-30 | 2011-08-17 | 江苏正大天晴药业股份有限公司 | 一种注射用异甘草酸镁冻干粉针剂及其制备方法 |
| JP2008222682A (ja) * | 2007-03-15 | 2008-09-25 | Kumamoto Univ | 線維化肺疾患治療薬、気道粘液分泌細胞過形成抑制剤および気道塞栓治療薬 |
| CN101669962A (zh) * | 2009-09-18 | 2010-03-17 | 杭州市第六人民医院 | 复合甘草酸氨基酸注射液及其制备方法和应用 |
| CA2809031C (en) * | 2010-08-25 | 2018-10-16 | Weijian Zhang | Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis |
| CN103156930A (zh) * | 2011-12-19 | 2013-06-19 | 张亚军 | 一种含芍药和甘草提取物的呼吸道给药制剂 |
| SG11201404522VA (en) | 2012-03-13 | 2014-10-30 | Respivert Ltd | Crystalline pi3 kinase inhibitors |
| CN102920936A (zh) * | 2012-09-17 | 2013-02-13 | 陈泉生 | 一种治疗呼吸道疾病的吸盐物及其制作方法 |
| CN104042573A (zh) * | 2014-06-03 | 2014-09-17 | 青岛市市立医院 | 一种异甘草酸镁冻干粉针剂及其制备方法 |
| CN106237297A (zh) * | 2016-08-30 | 2016-12-21 | 吉林紫鑫药业股份有限公司 | 一种用于治疗慢性支气管炎的药物组合物 |
-
2017
- 2017-04-14 SG SG11201809042SA patent/SG11201809042SA/en unknown
- 2017-04-14 EP EP17781942.2A patent/EP3443954A4/en active Pending
- 2017-04-14 BR BR112018071208-6A patent/BR112018071208A2/pt not_active Application Discontinuation
- 2017-04-14 CN CN202010842414.4A patent/CN111920785B/zh active Active
- 2017-04-14 EA EA201892350A patent/EA201892350A1/ru unknown
- 2017-04-14 AU AU2017251548A patent/AU2017251548B2/en active Active
- 2017-04-14 CN CN201780018629.0A patent/CN109069442B/zh active Active
- 2017-04-14 SG SG10202010192YA patent/SG10202010192YA/en unknown
- 2017-04-14 MX MX2018012461A patent/MX394106B/es unknown
- 2017-04-14 JP JP2018554375A patent/JP7166929B2/ja active Active
- 2017-04-14 MY MYPI2018703789A patent/MY204600A/en unknown
- 2017-04-14 WO PCT/CN2017/080583 patent/WO2017177966A1/zh not_active Ceased
- 2017-04-14 KR KR1020187033045A patent/KR102410183B1/ko active Active
- 2017-04-14 US US16/093,087 patent/US20190117568A1/en not_active Abandoned
-
2018
- 2018-10-12 PH PH12018502195A patent/PH12018502195A1/en unknown
-
2020
- 2020-08-07 US US16/988,289 patent/US11534398B2/en active Active
-
2021
- 2021-08-02 JP JP2021126412A patent/JP7309791B2/ja active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396368A (zh) * | 2007-09-29 | 2009-04-01 | 江苏正大天晴药业股份有限公司 | 异甘草酸或其盐在治疗过敏性鼻炎中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| 异甘草酸镁注射液的临床应用;李艳丽，等;《实用药物与临床》;20111231;第14卷(第6期);521-522 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7309791B2 (ja) | 2023-07-18 |
| MX2018012461A (es) | 2019-09-18 |
| US20200368158A1 (en) | 2020-11-26 |
| MY204600A (en) | 2024-09-05 |
| JP2021176903A (ja) | 2021-11-11 |
| EP3443954A1 (en) | 2019-02-20 |
| US11534398B2 (en) | 2022-12-27 |
| PH12018502195A1 (en) | 2019-09-23 |
| SG10202010192YA (en) | 2020-11-27 |
| BR112018071208A2 (pt) | 2019-02-12 |
| US20190117568A1 (en) | 2019-04-25 |
| CN109069442B (zh) | 2020-09-04 |
| AU2017251548B2 (en) | 2022-02-17 |
| EP3443954A4 (en) | 2019-11-20 |
| EA201892350A1 (ru) | 2019-06-28 |
| JP2019511556A (ja) | 2019-04-25 |
| CN109069442A (zh) | 2018-12-21 |
| KR102410183B1 (ko) | 2022-06-17 |
| WO2017177966A1 (zh) | 2017-10-19 |
| KR20180132143A (ko) | 2018-12-11 |
| AU2017251548A1 (en) | 2018-11-15 |
| JP7166929B2 (ja) | 2022-11-08 |
| SG11201809042SA (en) | 2018-11-29 |
| CN111920785A (zh) | 2020-11-13 |
| MX394106B (es) | 2025-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090197941A1 (en) | Pharmaceutical Compositons for the Treatment of Chronic Obstructive Pulmonary Disease | |
| JP2021102620A (ja) | 乾燥粉末配合および使用方法 | |
| US20170209464A1 (en) | Combinations of formoterol and budesonide for the treatment of copd | |
| US20160193253A1 (en) | Methods and materials for treating lung disorders | |
| CN111920785B (zh) | 异甘草酸或其盐的吸入制剂及其应用 | |
| Thamby et al. | Retrospective studies on drug utilization patterns of asthmatics in a Government hospital in Kedah, Malaysia | |
| CN118526500B (zh) | 利匹韦林的医药新用途 | |
| JP2021176903A5 (enExample) | ||
| HK1261173B (en) | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation | |
| HK1261173A1 (en) | Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use of the inhaled preparation | |
| CN115337311A (zh) | 一种治疗呼吸系统疾病的组合物及其制备方法 | |
| EA040563B1 (ru) | Применение препарата для ингаляции на основе изоглицирризината магния для лечения заболеваний дыхательной системы | |
| WO2021156839A1 (en) | Composition in the form of powder containing an extract of cannabis sativa for the treatment of inflammations or infections or allergies of the respiratory system and /or hypersecretion of the mucus, and device for its dosage | |
| WO2022166724A1 (zh) | 一种福多司坦吸入用溶液制剂及其制备方法和用途 | |
| CN113491676B (zh) | 一种利巴韦林的雾化吸入用溶液及制备方法 | |
| JPWO2017177966A5 (enExample) | ||
| CN119112892A (zh) | 伐诺司林二盐酸盐在制备抗慢性阻塞性肺病药物中的应用 | |
| CN117442588A (zh) | 一种吸入用人干扰素α2b溶液及其制备方法 | |
| CN119424603A (zh) | 复方多黏菌素的吸入制剂及其在制备治疗肺部感染的药物中的应用 | |
| Pawar et al. | Insights of Dry Powder Inhaler: An Emerging Potential Drug Delivery with Novel Therapeutic Carriers | |
| JP2022014868A (ja) | 慢性閉塞性肺疾患の急性増悪の治療薬の調製におけるＴａｎｒｅｑｉｎｇの応用 | |
| CN119258161A (zh) | 一种提高呼吸道免疫力的中药组合物及其应用 | |
| CA3204080A1 (en) | Compositions, devices, and methods for treating respiratory disorders | |
| CN116983288A (zh) | 一种口鼻吸入用汉黄芩素制剂在制备治疗脑胶质瘤药物中的应用 | |
| CN118542855A (zh) | 一种吸入制剂、吸入装置及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230922 Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd. Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. |